PDCD1 and neoplasm: This combination therapy leverages the dual mechanisms of immune checkpoint inhibition, where ipilimumab targets and blocks CTLA-4 to boost T-cell activity, while nivolumab inhibits PD-1, together creating a synergistic enhancement of the anti-tumor immune response.